TenQ · fact sheet · filings current to · price as of
Johnson & Johnson (JNJ)
A mixed picture - strengths and real weaknesses - 19 of 28 checks passed.
Latest close : $275.23, -1.1% on the day; -1.1% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $275.23 |
| Market cap | $663.3B |
| 52-week range | $170.32 - $278.43 |
| P/E | 31.8x |
| P/E, own 6-year median | 19.6x |
| P/S | 6.8x |
| Free cash flow yield | 3.4% |
| Dividend yield | - |
| Revenue (TTM) | $97.9B |
| Net income (TTM) | $21.0B |
| Free cash flow (TTM) | $22.2B |
| Gross margin | 67.9% |
| Operating margin | 22.2% |
| Return on equity | 24.8% |
| Revenue growth (1y) | +8.1% |
| Revenue CAGR (3y) | - |
| Debt / equity | 0.58x |
| Cash & short-term investments | $20.8B |
| Shares outstanding | 2,409.9m (cover page of the latest filing, 2026-07-17) |
The score: 19 of 28 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is JNJ stock cheap or expensive right now?
Value · 1 of 5 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Johnson & Johnson still growing?
Growth · not scored. Not enough data to score this fairly - the checks below show exactly what's missing. (earnings at or below zero at either end; under 3 years of history; under 3 years of per-share history) chapter →
Does Johnson & Johnson make real money?
Quality · 6 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Johnson & Johnson survive a bad year?
Health · 4 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Johnson & Johnson hand back to shareholders?
Shareholder returns · not scored. Not enough data to score this fairly - the checks below show exactly what's missing. (no dividend in the last three years; under 3 years of share counts) chapter →
Which way is JNJ trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling JNJ?
Open-market buys: $0.00 · sells: $118M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Pfizer (PFE) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.